Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Articles|October 5, 2023

Sharp Acquires Berkshire Sterile Manufacturing

Author(s)Susan Haigney

With the acquisition, Sharp plans on offering fully integrated small-to-medium scale sterile injectable services.

Sharp, a packaging and clinical trial supply services company, announced on Oct. 5, 2023 the acquisition of Berkshire Sterile Manufacturing (BSM), a contract development and manufacturing organization (CDMO) located in Massachusetts that offers clinical and commercial sterile injectable products. Sharp anticipates the acquisition will allow the company to offer fully integrated small-to-medium scale sterile injectable services.

Sharp currently offers clinical supply, packaging, and distribution solutions. BSM’s sterile manufacturing expertise and CDMO services will complement Sharp’s services, according to the company, offering customers services from sterile drug manufacturing to clinical trial services, commercial packaging, and distribution. BSM manufactures small-scale sterile clinical and commercial drug products and has fill/finish services that include isolator-based sterile filling of vials, syringes, and cartridges with lyophilization capabilities.

“The market continues to demand expertise and capacity in sterile manufacturing due in part to the growth in rare and orphan disease therapies. With sterile injectables a huge part of addressing this unmet medical need, the acquisition of BSM allows Sharp to provide a fully integrated solution for our biopharma clients that is a natural extension of our existing injectables and clinical packaging expertise,” said Kevin Orfan, president and CEO of Sharp, in a press release. “This acquisition, which builds on the existing partnership between our two companies, will greatly benefit our clients, creating an efficient manufacturing and distribution service for biotech companies developing sterile injectable products across the world.”

Dr. Shawn Kinney, BSM’s co-founder and CEO, who will join Sharp’s Senior Leadership Team, stated in the press release, “This is an exciting development for everyone at BSM and for our clients, who will benefit from a seamless downstream packaging, labeling, storage, and distribution service through Sharp’s network of facilities and expertise. With Sharp’s support, I am looking forward to the opportunity to grow the sterile manufacturing business and to broaden our reach in the service of our clients and their patients.”

Source: Sharp

Related to this article

View more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more